Bronchodilator effects of salmeterol/fluticasone propionate (SFC) in patients with COPD

Bronchodilator effects of salmeterol/fluticasone propionate (SFC) in patients with COPD - Bronchodilator effects of salmeterol/fluticasone propionate (SFC) in patients with COPD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002764

Enrollment

Registered

2009-11-13

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Inhaled SFC (50/250) twice daily.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: COPD patients meet the GOLD guidelines (post-bronchodilator FEV1/forced vital capacity (FVC) ratio < 70%).

Exclusion criteria

Exclusion criteria: 1) Asthma 2) Subjects had taken corticosteroids (either oral or inhaled) 3) Subjects had been suffering from COPD exacerbation. 4) Patients who are considered inappropriate by doctor.

Design outcomes

Primary

Measure	Time frame
Indices of chest CT	—

Secondary

Measure	Time frame
Parameters of pulmonary function Cell counts of induced sputum Scores of quality of life	—

Countries

Japan

Contacts

Public ContactMakoto Hoshino

Atami Hospita International University of Health and Welfare Department of Respiratory Medicine

hoshino@iuhw.ac.jp0557819171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026